MusclePharm (MSLPQ) 10-Q2012 Q2 Quarterly report

Filed: 20 Aug 12, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: acquired, add, al, analgesic, appointed, back, began, billion, Bishop, Bossung, breach, Canadian, cap, Center, CFO, claim, Clark, compliance, comprised, consumer, contemplated, correspondingly, County, currency, cycle, deeper, Dollar, Eastern, effectuate, effort, Energel, Enerjel, Environmental, ERC, familiar, Florida, foreign, fully, Fuse, harbor, Idaho, infringement, ingested, injunctive, intellectual, isometric, JMJ, Justin, Keener, largest, Lone, Los, margin, Matrix, meaningful, monetary, mutual, objection, personal, promptly, proposed, protect, protection, purpose, put, recover, register, regular, release, relief, reset, rose, safe, Science, Shred, Southern, split, standard, Star, Superior, Swole, Tennessee, today, topical, trademark, translated, translation, Turbo, unrealized, urge, USA, USPTO, variety, voluntarily, William

Removed: adversely, branded, constitute, exercisable, exercised, Foundation, hedging, incentive, November, obligated, offset, organized, PEO, PFO, recapitalization, Sanitation, shorter

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

MSLPQ similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE

SARBANES-OXLEY ACT OF 2002

In connection with this Quarterly Report of MusclePharm Corporation (the “Company”), on Form 10-Q for the quarter ended June 30, 2012, as filed with the U.S. Securities and Exchange Commission on the date hereof, I, L. Gary Davis, Principal Financial Officer of the Company, certify to the best of my knowledge, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

Such Quarterly Report on Form 10-Q for the quarter ended June 30, 2012, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in such Quarterly Report on Form 10-Q for the quarter ended June 30, 2012, fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 20, 2012	By:	/s/ L. Gary Davis
		L. Gary Davis
		Principal Financial Officer MusclePharm Corporation

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.